Yong Jia

发表

(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors.

Nanxin Li, Jennifer L. Harris, Jianwei Che, 2015, ACS medicinal chemistry letters.

Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.

Nanxin Li, A. Kreusch, Shenlin Huang, 2012, ACS medicinal chemistry letters.

Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes

Matthew S. Tremblay, Shanshan Yan, B. Laffitte, 2019, ACS Omega.

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.

H. M. Petrassi, P. McNamara, Minhua Qiu, 2020, Journal of medicinal chemistry.

Structure-Based Design of Selective LONP1 Inhibitors for Probing In Vitro Biology.

Laura J. Kingsley, S. Bender, M. Vaillancourt, 2021, Journal of medicinal chemistry.

Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Ce

Chun Xing Li, S. Bender, G. Spraggon, 2016, Journal of medicinal chemistry.

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

Haikuo Zhang, Gerald Lelais, Kwok-Kin Wong, 2016 .

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Glen Spraggon, Scott A Lesley, Nanxin Li, 2010, The Biochemical journal.

EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor.

J. Barretina, Jennifer L. Harris, J. Engelman, 2016, Cancer research.

Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies

M. Warmuth, A. Brinker, X. Gu, 2008, Expert opinion on drug discovery.

HTRF Kinase Assay Development and Methods in Inhibitor Characterization.

J. Juarez, Yong Jia, M. Manuia, 2016, Methods in molecular biology.

Current status of HTRF® technology in kinase assays

Yong Jia, 2008, Expert opinion on drug discovery.

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

Tao Jiang, Bo Liu, Glen Spraggon, 2017, ACS medicinal chemistry letters.

Abstract 2585: Discovery of a potent covalent mutant-selective EGFR inhibitor - the journey from high throughput screening to EGF816

C. Li, S. Kasibhatla, I. Matushansky, 2015 .

Abstract 1734:In vitrocharacterization of EGF816, a third-generation mutant-selective EGFR inhibitor

Jennifer L. Harris, S. Bender, N. Pathan, 2014 .

Abstract 1733: EGF816, a novel covalent inhibitor of mutant-selective epidermal growth factor receptor, overcomes T790M-mediated resistance in NSCLC

S. Bender, M. Vaillancourt, S. Kasibhatla, 2014 .

A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.

P. McNamara, G. Harb, Shanshan Yan, 2020, ChemMedChem.

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors

P. Jänne, Jennifer L. Harris, M. Eck, 2016, Nature.

Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.

Sungjoon Kim, Nanxin Li, Jennifer L. Harris, 2010, The Biochemical journal.